Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Equity to Asset 0.58
NVS's Equity to Asset is ranked lower than
57% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NVS: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
NVS' s Equity to Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.59 Max: 0.65
Current: 0.58
0.51
0.65
Interest Coverage 11.66
NVS's Interest Coverage is ranked lower than
71% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. NVS: 11.66 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s Interest Coverage Range Over the Past 10 Years
Min: 11.66  Med: 16.22 Max: 30.91
Current: 11.66
11.66
30.91
F-Score: 5
Z-Score: 2.43
M-Score: -2.67
WACC vs ROIC
7.41%
7.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.67
NVS's Operating margin (%) is ranked higher than
74% of the 737 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.69 vs. NVS: 16.67 )
Ranked among companies with meaningful Operating margin (%) only.
NVS' s Operating margin (%) Range Over the Past 10 Years
Min: 16.72  Med: 20.76 Max: 22.35
Current: 16.67
16.72
22.35
Net-margin (%) 13.51
NVS's Net-margin (%) is ranked higher than
75% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. NVS: 13.51 )
Ranked among companies with meaningful Net-margin (%) only.
NVS' s Net-margin (%) Range Over the Past 10 Years
Min: 13.58  Med: 18.81 Max: 35.29
Current: 13.51
13.58
35.29
ROE (%) 8.98
NVS's ROE (%) is ranked higher than
59% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. NVS: 8.98 )
Ranked among companies with meaningful ROE (%) only.
NVS' s ROE (%) Range Over the Past 10 Years
Min: 8.95  Med: 14.79 Max: 25.73
Current: 8.98
8.95
25.73
ROA (%) 5.06
NVS's ROA (%) is ranked higher than
58% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NVS: 5.06 )
Ranked among companies with meaningful ROA (%) only.
NVS' s ROA (%) Range Over the Past 10 Years
Min: 5.19  Med: 8.59 Max: 16.19
Current: 5.06
5.19
16.19
ROC (Joel Greenblatt) (%) 37.30
NVS's ROC (Joel Greenblatt) (%) is ranked higher than
77% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.01 vs. NVS: 37.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 39.09  Med: 56.85 Max: 69.75
Current: 37.3
39.09
69.75
Revenue Growth (3Y)(%) 2.90
NVS's Revenue Growth (3Y)(%) is ranked lower than
60% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. NVS: 2.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.9  Med: 2.5 Max: 12.3
Current: 2.9
-3.9
12.3
EBITDA Growth (3Y)(%) -4.80
NVS's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.00 vs. NVS: -4.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.6  Med: 0.4 Max: 11.6
Current: -4.8
-7.6
11.6
EPS Growth (3Y)(%) -4.80
NVS's EPS Growth (3Y)(%) is ranked lower than
67% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. NVS: -4.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -7.1  Med: 3.2 Max: 82
Current: -4.8
-7.1
82
GuruFocus has detected 5 Warning Signs with Novartis AG $NVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NVS Guru Trades in Q1 2016

Tom Gayner 3,700 sh (New)
John Rogers 13,296 sh (+18.01%)
Sarah Ketterer 316,362 sh (+12.30%)
Jim Simons 3,264,498 sh (+5.61%)
Manning & Napier Advisors, Inc 3,638,373 sh (+3.73%)
Murray Stahl 29,250 sh (+1.74%)
Ken Fisher 6,287,099 sh (+1.59%)
PRIMECAP Management 20,938,858 sh (+0.82%)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Dodge & Cox 45,054,916 sh (-0.12%)
Tweedy Browne 237,664 sh (-1.87%)
Mario Gabelli 6,865 sh (-7.10%)
Mairs and Power 3,780 sh (-7.35%)
Eaton Vance Worldwide Health Sciences Fund 457,700 sh (-48.86%)
» More
Q2 2016

NVS Guru Trades in Q2 2016

John Rogers 14,818 sh (+11.45%)
Ken Fisher 6,363,641 sh (+1.22%)
Sarah Ketterer 319,351 sh (+0.94%)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Mairs and Power 3,780 sh (unchged)
Murray Stahl 29,250 sh (unchged)
PRIMECAP Management 20,831,508 sh (-0.51%)
Dodge & Cox 44,366,511 sh (-1.53%)
Tweedy Browne 233,783 sh (-1.63%)
Manning & Napier Advisors, Inc 3,564,657 sh (-2.03%)
Mario Gabelli 6,015 sh (-12.38%)
Jim Simons 2,260,598 sh (-30.75%)
Eaton Vance Worldwide Health Sciences Fund 255,700 sh (-44.13%)
» More
Q3 2016

NVS Guru Trades in Q3 2016

Mairs and Power 6,354 sh (+68.10%)
Jim Simons 2,515,098 sh (+11.26%)
Manning & Napier Advisors, Inc 3,752,105 sh (+5.26%)
Mario Gabelli 6,265 sh (+4.16%)
Sarah Ketterer 321,258 sh (+0.60%)
Kahn Brothers 27,643 sh (unchged)
Tom Gayner 3,700 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Murray Stahl 29,250 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 255,700 sh (unchged)
PRIMECAP Management 20,557,433 sh (-1.32%)
Dodge & Cox 43,581,886 sh (-1.77%)
Ken Fisher 6,065,150 sh (-4.69%)
Tweedy Browne 220,115 sh (-5.85%)
John Rogers 13,914 sh (-6.10%)
» More
Q4 2016

NVS Guru Trades in Q4 2016

Chris Davis 257,670 sh (New)
Manning & Napier Advisors, Inc 5,554,008 sh (+48.02%)
John Rogers 15,402 sh (+10.69%)
Dodge & Cox 45,734,721 sh (+4.94%)
PRIMECAP Management 21,246,828 sh (+3.35%)
Ken Fisher 6,074,870 sh (+0.16%)
First Eagle Investment 12,848 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Sarah Ketterer 318,018 sh (-1.01%)
Tweedy Browne 216,590 sh (-1.60%)
Kahn Brothers 27,071 sh (-2.07%)
Mairs and Power 6,053 sh (-4.74%)
Mario Gabelli 5,870 sh (-6.30%)
Jim Simons 2,287,000 sh (-9.07%)
Murray Stahl 24,850 sh (-15.04%)
Eaton Vance Worldwide Health Sciences Fund 172,411 sh (-32.57%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:MRK, NYSE:PFE, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, OTCPK:BAYZF, NYSE:BMY, NYSE:LLY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHJTF, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.

Novartis AG was incorporated on February 29, 1996 under the laws of Switzerland as a stock corporation (Aktiengesellschaft) with an indefinite duration. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. It is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of healthcare products led by innovative pharmaceuticals. Its broad portfolio includes innovative pharmaceuticals and oncology medicines, generic and biosimilar medicines and eye care devices. It operates in the following segments: Innovative Medicines (formerly named Pharmaceuticals): Innovative patent-protected prescription medicines; Sandoz: Generic pharmaceuticals and biosimilars; and Alcon: Surgical and vision care products.

Top Ranked Articles about Novartis AG

Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...
Does Biotech’s Recent Bounce Have Legs? Examining 3 Big Pharma stocks that dominate the making of cancer-fighting treatments
The beleaguered biotechology sector, which has endured political controversy amid charges of price gouging, is now on an upward trajectory. The Nasdaq Biotechnology Index, after falling 17.46% year to date, has jumped 9.04% over the past month. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 28.00
NVS's P/E(ttm) is ranked higher than
51% of the 562 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.03 vs. NVS: 28.00 )
Ranked among companies with meaningful P/E(ttm) only.
NVS' s P/E(ttm) Range Over the Past 10 Years
Min: 5.7  Med: 15.92 Max: 29.97
Current: 28
5.7
29.97
Forward P/E 15.87
NVS's Forward P/E is ranked lower than
55% of the 87 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.73 vs. NVS: 15.87 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.00
NVS's PE(NRI) is ranked higher than
52% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.21 vs. NVS: 28.00 )
Ranked among companies with meaningful PE(NRI) only.
NVS' s PE(NRI) Range Over the Past 10 Years
Min: 10.63  Med: 18.23 Max: 31.15
Current: 28
10.63
31.15
Price/Owner Earnings (ttm) 16.80
NVS's Price/Owner Earnings (ttm) is ranked higher than
78% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.84 vs. NVS: 16.80 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
NVS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.18  Med: 15.7 Max: 23.92
Current: 16.8
7.18
23.92
P/B 2.40
NVS's P/B is ranked higher than
63% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. NVS: 2.40 )
Ranked among companies with meaningful P/B only.
NVS' s P/B Range Over the Past 10 Years
Min: 1.69  Med: 2.44 Max: 3.95
Current: 2.4
1.69
3.95
P/S 3.79
NVS's P/S is ranked lower than
56% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.12 vs. NVS: 3.79 )
Ranked among companies with meaningful P/S only.
NVS' s P/S Range Over the Past 10 Years
Min: 1.89  Med: 3.26 Max: 5.01
Current: 3.79
1.89
5.01
PFCF 22.79
NVS's PFCF is ranked higher than
50% of the 223 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.98 vs. NVS: 22.79 )
Ranked among companies with meaningful PFCF only.
NVS' s PFCF Range Over the Past 10 Years
Min: 7.05  Med: 17.08 Max: 26.68
Current: 22.79
7.05
26.68
POCF 16.30
NVS's POCF is ranked higher than
56% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.86 vs. NVS: 16.30 )
Ranked among companies with meaningful POCF only.
NVS' s POCF Range Over the Past 10 Years
Min: 5.77  Med: 13.23 Max: 19.3
Current: 16.3
5.77
19.3
EV-to-EBIT 23.13
NVS's EV-to-EBIT is ranked lower than
59% of the 570 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.59 vs. NVS: 23.13 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.6 Max: 27
Current: 23.13
8.5
27
EV-to-EBITDA 13.38
NVS's EV-to-EBITDA is ranked higher than
61% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.67 vs. NVS: 13.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.2 Max: 18.1
Current: 13.38
7.3
18.1
Shiller P/E 16.01
NVS's Shiller P/E is ranked higher than
89% of the 158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.89 vs. NVS: 16.01 )
Ranked among companies with meaningful Shiller P/E only.
NVS' s Shiller P/E Range Over the Past 10 Years
Min: 9.68  Med: 14.69 Max: 21.57
Current: 16.01
9.68
21.57
Current Ratio 1.12
NVS's Current Ratio is ranked lower than
83% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.38 vs. NVS: 1.12 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.4 Max: 2.83
Current: 1.12
0.96
2.83
Quick Ratio 0.84
NVS's Quick Ratio is ranked lower than
80% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. NVS: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.17 Max: 2.48
Current: 0.84
0.7
2.48
Days Inventory 135.81
NVS's Days Inventory is ranked lower than
60% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.25 vs. NVS: 135.81 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 150.76 Max: 183.45
Current: 135.81
117.82
183.45
Days Sales Outstanding 62.61
NVS's Days Sales Outstanding is ranked higher than
61% of the 629 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.25 vs. NVS: 62.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.6 Max: 70.59
Current: 62.61
56.31
70.59
Days Payable 104.96
NVS's Days Payable is ranked higher than
70% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.46 vs. NVS: 104.96 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 104.96
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.52
NVS's Dividend Yield is ranked higher than
90% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. NVS: 3.52 )
Ranked among companies with meaningful Dividend Yield only.
NVS' s Dividend Yield Range Over the Past 10 Years
Min: 1.49  Med: 3.35 Max: 5.11
Current: 3.52
1.49
5.11
Dividend Payout 0.96
NVS's Dividend Payout is ranked higher than
68% of the 398 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. NVS: 0.96 )
Ranked among companies with meaningful Dividend Payout only.
NVS' s Dividend Payout Range Over the Past 10 Years
Min: 0.4  Med: 0.64 Max: 0.97
Current: 0.96
0.4
0.97
Dividend Growth (3y) 7.60
NVS's Dividend Growth (3y) is ranked lower than
54% of the 284 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.00 vs. NVS: 7.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
NVS' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 7.15 Max: 18.5
Current: 7.6
0
18.5
Forward Dividend Yield 3.56
NVS's Forward Dividend Yield is ranked higher than
85% of the 613 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NVS: 3.56 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.52
NVS's Yield on cost (5-Year) is ranked higher than
88% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.21 vs. NVS: 4.52 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.92  Med: 4.32 Max: 6.58
Current: 4.52
1.92
6.58
3-Year Average Share Buyback Ratio 0.70
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 440 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.20 vs. NVS: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.05 Max: 2.4
Current: 0.7
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 14.33
NVS's Price/Tangible Book is ranked lower than
91% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. NVS: 14.33 )
Ranked among companies with meaningful Price/Tangible Book only.
NVS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.68  Med: 5.26 Max: 35.21
Current: 14.33
2.68
35.21
Price/Projected FCF 1.23
NVS's Price/Projected FCF is ranked higher than
82% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.75 vs. NVS: 1.23 )
Ranked among companies with meaningful Price/Projected FCF only.
NVS' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.16 Max: 2.39
Current: 1.23
0.76
2.39
Price/Median PS Value 1.16
NVS's Price/Median PS Value is ranked lower than
51% of the 695 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.12 vs. NVS: 1.16 )
Ranked among companies with meaningful Price/Median PS Value only.
NVS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.72  Med: 1.12 Max: 1.61
Current: 1.16
0.72
1.61
Price/Graham Number 4.15
NVS's Price/Graham Number is ranked lower than
79% of the 457 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. NVS: 4.15 )
Ranked among companies with meaningful Price/Graham Number only.
NVS' s Price/Graham Number Range Over the Past 10 Years
Min: 1.24  Med: 2.48 Max: 6.59
Current: 4.15
1.24
6.59
Earnings Yield (Greenblatt) (%) 4.30
NVS's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. NVS: 4.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.7  Med: 6.4 Max: 11.8
Current: 4.3
3.7
11.8
Forward Rate of Return (Yacktman) (%) 4.77
NVS's Forward Rate of Return (Yacktman) (%) is ranked lower than
57% of the 351 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.42 vs. NVS: 4.77 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NVS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1  Med: 13.8 Max: 61.6
Current: 4.77
1
61.6

More Statistics

Revenue (TTM) (Mil) $49,436
EPS (TTM) $ 2.80
Beta0.75
Short Percentage of Float0.27%
52-Week Range $66.93 - 83.58
Shares Outstanding (Mil)2,374.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 49,460 52,434 54,894
EPS ($) 4.76 5.26 5.84
EPS w/o NRI ($) 4.76 5.26 5.84
EPS Growth Rate
(3Y to 5Y Estimate)
3.38%
Dividends Per Share ($) 2.85 3.03 3.18
» More Articles for NVS

Headlines

Articles On GuruFocus.com
Novartis Has Bright Future Feb 01 2017 
2 Top Health Care Dividend Stocks Jan 12 2017 
7 Stocks With Low P/S Ratios Jan 11 2017 
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
Novartis Is Surviving Oct 03 2016 
A Double Dose of Trouble at Novartis Sep 22 2016 

More From Other Websites
Blog Coverage Ionis Pharma Closed on its Collaboration Agreement with Novartis Following Clearance... Feb 17 2017
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback Feb 16 2017
GlaxoSmithKline’s Valuation Compared to Its Peers Feb 16 2017
Bristol-Myers: Don't Bet on a Pfizer Acquisition Feb 15 2017
Bristol-Myers Squibb: Takeover Target? Feb 14 2017
4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017
Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education Feb 14 2017
These N.Y.C.-area doctors received the most payments from drug and device makers Feb 14 2017
10 Most Diverse Companies In The US Feb 10 2017
UBS Makes First Big 2017 Addition to Dividend Rulers Stocks List Feb 09 2017
Propeller Health Enters into Collaboration to Connect Breezhaler™ Devices to the Propeller... Feb 08 2017
Novartis’s Valuation after the 4Q16 Results Feb 03 2017
Why the Majority of Analysts Deem Novartis a ‘Buy’ Feb 03 2017
Novartis’s Financial Guidance and Priorities for 2017 Feb 03 2017
Novartis’s Recent Developments Feb 02 2017
Novartis (NVS) Votubia Gets EU Approval for Label Expansion Feb 02 2017
Inside Novartis’s Eye Care Performance in 4Q16 Feb 02 2017
Inside Novartis’s Generics Performance in 4Q16 Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)